A clinical decision support tool may help to optimise vedolizumab therapy in Crohn’s disease
Alimentary Pharmacology & Therapeutics2019Vol. 51(5), pp. 553–564
Citations Over TimeTop 10% of 2019 papers
Parambir S. Dulai, Aurélien Amiot, Laurent Peyrin‐Biroulet, Vipul Jairaith, Mélanie Serrero, Jérôme Filippi, Siddharth Singh, Benjamin Pariente, Edward V. Loftus, Xavier Roblin, Sunanda V. Kane, Anthony Buisson, Corey A. Siegel, Yoram Bouhnik, William J. Sandborn, Karen Lasch, Maria Rosario, Brian G. Feagan, Daniela Bojic, Caroline Trang-Poisson, Bo Shen, Romain Altwegg, Bruce E. Sands, Jean‐Frédéric Colombel, Franck Carbonnel
Abstract
We further extended the clinical utility of a previously validated VDZ CDST, which accurately predicts at baseline exposure-efficacy relationships and rapidity of onset of action and could be used to help identify patients who would most benefit from interval shortening and those most likely to require surgery while on active therapy.
Related Papers
- → Vedolizumab for induction and maintenance of remission in Crohn’s disease(2020)1 cited
- → Mo1845 - Higher Serum Concentrations of Vedolizumab are Associated with Superior Endoscopic Outcomes in Crohn's Disease: Data from the Love-CD Trial(2018)1 cited
- → Tu1268 Effect of Vedolizumab on Health-Related Quality of Life in Patients With Crohn's Disease(2015)
- Vedolizumab in Crohn Disease genesis-sefh drug evaluation report* Vedolizumab en Enfermedad de Crohn; Informe de evaluación GENESIS-SEFH(2015)
- → Faculty Opinions recommendation of Vedolizumab as induction and maintenance therapy for Crohn's disease.(2013)